Dana-Farber's Toni Choueiri, MD, presents phase 3 LITESPARK-022 at ASCO GU (IMAGE)

Dana-Farber Cancer Institute

Dana-Farber's Toni Choueiri, MD, presents phase 3 LITESPARK-022 at ASCO GU

Caption

Toni K. Choueiri, MD, director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, presents findings from the phase 3 LITESPARK-022 study at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco, California.

Credit

Dana-Farber Cancer Institute

Usage Restrictions

Kindly credit Dana-Farber Cancer Institute

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.